Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,232 stopped studies mapped to B-Cell Malignant Neoplasm and descendants · 88% state a reason
Over the 1,232 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00086840 | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell… | Phase 2 | terminated | Apr 20, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00036855 | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | Phase 1 | terminated | Sep 17, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | Phase 2 | withdrawn | Nov 4, 2010 | Milton S. Hershey Medical Center | Study never undertaken | Other (stated, no rule matched) |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV… | Phase 2 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00902525 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | Phase 2 | terminated | May 15, 2009 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | After enrolling 25 patients an interim analysis was done.The study was discontinued in the absence… | Efficacy / futility |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in… | Phase 2 | terminated | Feb 25, 2009 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00541424 | Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma | — | withdrawn | Oct 10, 2007 | M.D. Anderson Cancer Center | No study recruitment due to time constraints and lack of support. | Enrollment / accrual |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 2 | terminated | Mar 14, 2008 | David Rizzieri | funding | Funding |
| NCT00108108 | Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is… | Phase 1 | terminated | Apr 15, 2005 | Novartis Pharmaceuticals | Slow enrollment and minimal preliminary biological and clinical efficacy. | Efficacy / futility |
| NCT01300793 | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide(V-RICE) | Phase 1 | terminated | Feb 23, 2011 | University of California, San Francisco | closed for low accrual and no data is available. | Enrollment / accrual |
| NCT01269203 | Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple… | Phase 2 | withdrawn | Jan 4, 2011 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single… | Phase 2 | withdrawn | Aug 7, 2012 | Gilead Sciences | not stated | Not stated |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC)… | Phase 1 / Phase 2 | terminated | Nov 19, 2008 | Emory University | not stated | Not stated |
| NCT00968331 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients… | Phase 2 | terminated | Aug 31, 2009 | University of Bologna | The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and… | Other (stated, no rule matched) |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell… | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT00242827 | Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple… | Phase 2 | terminated | Oct 21, 2005 | Cephalon | not stated | Not stated |
| NCT00726869 | A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized… | Phase 1 | terminated | Aug 1, 2008 | Abbott | Enrollment has been halted | Enrollment / accrual |
| NCT00962715 | Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon… | Phase 1 / Phase 2 | withdrawn | Aug 20, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00081887 | Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic… | Phase 1 | terminated | Apr 27, 2004 | M.D. Anderson Cancer Center | low accrual | Enrollment / accrual |
| NCT00800566 | Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) | Phase 1 | withdrawn | Dec 2, 2008 | M.D. Anderson Cancer Center | Sponsor terminated. | Other (stated, no rule matched) |
| NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory… | Phase 2 | terminated | Feb 13, 2009 | Piramal Enterprises Limited | The study was terminated based on interim results and all subjects were off study at that time. No… | Safety / toxicity |
| NCT00368121 | EMMA-1 (Erbitux for Multiple Myeloma)(EMMA-1) | Phase 2 | terminated | Aug 24, 2006 | Prof. Dr. Andreas Engert | Lack of recruitable patients | Enrollment / accrual |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
| NCT00151736 | Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of… | Phase 2 | terminated | Sep 9, 2005 | Cephalon | not stated | Not stated |
| NCT01492881 | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory… | Phase 2 | withdrawn | Dec 15, 2011 | UNC Lineberger Comprehensive Cancer Center | Doxil is currently unavailable | Other (stated, no rule matched) |
| NCT00128921 | Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Aug 10, 2005 | University of Arkansas | study terminated due to low accrual | Enrollment / accrual |
| NCT00515138 | A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE)… | Early Phase 1 | terminated | Aug 13, 2007 | University of California, San Francisco | Investigator left institution. 7 patients accrued and there is insufficient data to analyze. | Investigator |
| NCT00171925 | Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I | Phase 3 | terminated | Sep 15, 2005 | Novartis Pharmaceuticals | Recruitment in study could not be reached after 8 yrs of recruiting | Enrollment / accrual |
| NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple… | Phase 2 | terminated | Aug 18, 2006 | Accelerated Community Oncology Research Network | Study was closed to enrollment when it became clear that enrollment was too slow to complete full… | Enrollment / accrual |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | Phase 1 | withdrawn | Oct 14, 2011 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | Phase 2 | terminated | May 21, 2007 | University of Florida | PI left our institution | Investigator |
| NCT01175278 | Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body… | N/A | withdrawn | Aug 4, 2010 | H. Lee Moffitt Cancer Center and Research Institute | No enrollment | Enrollment / accrual |
| NCT00758693 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or… | Phase 2 | withdrawn | Sep 25, 2008 | University of Kentucky | Funding was withdrawn due to insufficient accrual | Enrollment / accrual |
| NCT00504491 | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia(R-CHOP) | Phase 2 | withdrawn | Jul 20, 2007 | CABYC | IMP new owner decision | Other (stated, no rule matched) |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for… | Phase 1 | terminated | May 15, 2007 | M.D. Anderson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | Phase 2 | terminated | May 21, 2010 | The Christie NHS Foundation Trust | Potential safety issue of second primary malignancies in patients treated with lenalidomide. | Safety / toxicity |
| NCT00712062 | Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System… | Phase 2 | withdrawn | Jul 9, 2008 | University of Florida | Lack of accrual | Enrollment / accrual |
| NCT00107614 | DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's… | Phase 2 | terminated | Apr 6, 2005 | University of Arkansas | Terminated due to poor accrual. | Enrollment / accrual |
| NCT00573391 | Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous… | Phase 3 | terminated | Dec 14, 2007 | University of Arkansas | low accrual | Enrollment / accrual |
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | Phase 2 | terminated | Sep 3, 2007 | CancerCare Manitoba | Terminated due to poor accrual. | Enrollment / accrual |
| NCT00880867 | Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell… | Phase 1 | terminated | Apr 14, 2009 | Nevada Cancer Institute | Low enrollment | Enrollment / accrual |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic… | Phase 2 | terminated | May 18, 2010 | Nevada Cancer Institute | Low enrollment | Enrollment / accrual |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a… | Phase 2 | withdrawn | May 26, 2010 | Nevada Cancer Institute | PI left institution | Investigator |
| NCT00768339 | A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Oct 8, 2008 | Aegera Therapeutics | Slow recruitment | Enrollment / accrual |
| NCT01116128 | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory…(D-MP) | Phase 2 | terminated | May 4, 2010 | Fondazione EMN Italy Onlus | difficulty in enrolling patients | Enrollment / accrual |
| NCT00577668 | A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone… | Phase 2 | withdrawn | Dec 20, 2007 | University of Arkansas | Poor accrual | Enrollment / accrual |
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple… | Phase 2 | terminated | Sep 22, 2005 | Hoosier Cancer Research Network | Study terminated due to low patient enrollment. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 24, 2013source: clinicaltrials